I5409

IRAK-1/4 Inhibitor I

≥98% (HPLC), solid

• Synonym(e): 1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole
• Empirische Formel (Hill-System): C₂₀H₂₁N₅O₄
• CAS-Nummer: 509093-47-4
• Molekulargewicht: 395.41
• MDL-Nummer: MFCD09752602
• UNSPSC-Code: 51111800
• PubChem Substanz-ID: 329815384
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: solid
• Farbe: off-white to light yellow
• Löslichkeit: DMSO: ≥5 mg/mL
• Lagertemp.: 2-8°C
• SMILES String: O=C(C1=CC([N+]([O-])=O)=CC=C1)NC2=NC3=C(N2CCN4CCOCC4)C=CC=C3
• InChI: 1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
• InChIKey: QTCFYQHZJIIHBS-UHFFFAOYSA-N

Beschreibung

Anwendung

IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines.

Biochem./physiol. Wirkung

IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC₅₀ values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested.

IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit inhibitory effects on the nuclear factor (NF)-κB signaling pathway.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Persönliche Schutzausrüstung: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges